<!doctype html>
<html lang="en">
<head>
  <meta charset="utf-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <title>Autism in Women — What Doctors Still Miss (Expanded 2025) — Part 1</title>
  <meta name="description" content="Clinically precise, patient-inclusive guide to autism in women: phenotype, masking, neurobiology (DMN/salience/cerebellum), genetics/epigenetics (female protective effect), neuroendocrinology (estrogen/oxytocin/vasopressin). Part 1 of 2." />
  <link rel="icon" href="/favicon.ico" />
  <!-- Open Graph -->
  <meta property="og:type" content="article" />
  <meta property="og:site_name" content="Women & Psychiatry — Second Opinion" />
  <meta property="og:title" content="Autism in Women — What Doctors Still Miss (Expanded 2025) — Part 1" />
  <meta property="og:description" content="Why many autistic women are still missed; the female phenotype; brain networks; genetics & hormones. Part 1 (of 2)." />
  <meta property="og:image" content="https://women-and-psychiatry.github.io/women-and-psychiatry-second-opinion.com/og-image.jpg" />
  <!-- Twitter -->
  <meta name="twitter:card" content="summary_large_image" />
  <meta name="twitter:title" content="Autism in Women — What Doctors Still Miss (Expanded 2025) — Part 1" />
  <meta name="twitter:description" content="Phenotype, masking, neurobiology, genetics, hormones — rigorous and humane. Part 1 of 2." />
  <meta name="twitter:image" content="https://women-and-psychiatry.github.io/women-and-psychiatry-second-opinion.com/og-image.jpg" />
  <style>
    :root{
      --bg:#0d112b; --panel:#121735; --ink:#f3f6ff; --ink-dim:#c9d0f8;
      --accent:#6ea8fe; --accent-2:#c084fc; --muted:#9aa3c7; --ok:#3ddc97;
      --shadow:0 10px 30px rgba(0,0,0,.25);
      --radius:16px; --radius-lg:22px; --maxw:900px;
    }
    html,body{height:100%}
    body{margin:0; font-family:ui-sans-serif,system-ui,-apple-system,Segoe UI,Roboto,Helvetica,Arial; color:var(--ink); background:var(--bg); line-height:1.7}
    .wrap{max-width:var(--maxw); margin:clamp(20px,5vw,64px) auto; padding:0 20px}
    header.hero{background:linear-gradient(135deg, rgba(110,168,254,.12), rgba(192,132,252,.10));
      border:1px solid rgba(255,255,255,.10); box-shadow:var(--shadow);
      border-radius:var(--radius-lg); padding:clamp(24px,5vw,48px)}
    .hero h1{margin:0 0 10px; font-size:clamp(28px,5vw,48px)}
    .hero p.lead{margin:8px 0 0; color:var(--ink-dim); font-size:clamp(16px,2.4vw,20px)}
    .badge{display:inline-flex; align-items:center; gap:.5rem;
      background:rgba(255,255,255,.08); border:1px solid rgba(255,255,255,.12);
      color:var(--ink-dim); padding:.35rem .7rem; border-radius:999px; font-size:.85rem}
    .badge .dot{width:8px;height:8px;border-radius:50%;background:var(--ok);box-shadow:0 0 0 3px rgba(61,220,151,.18)}
    nav.toc{margin:28px 0; background:rgba(255,255,255,.06); border:1px solid rgba(255,255,255,.10);
      border-radius:var(--radius); padding:16px}
    nav.toc h2{font-size:1rem; margin:0 0 10px; color:var(--ink-dim)}
    nav.toc a{display:inline-block; color:var(--ink); text-decoration:none;
      padding:.2rem .55rem; margin:.15rem; border-radius:999px; border:1px solid rgba(255,255,255,.1)}
    nav.toc a:hover{background:rgba(255,255,255,.09)}
    section{background:rgba(255,255,255,.06); border:1px solid rgba(255,255,255,.10);
      border-radius:var(--radius); padding:clamp(18px,2.5vw,28px); margin:16px 0; box-shadow:var(--shadow)}
    section h2{margin-top:0; font-size:clamp(22px,3vw,32px)}
    h3{margin-top:1.1em}
    p{margin:.5rem 0 1rem}
    ul{margin:.2rem 0 1rem 1.25rem}
    li{margin:.35rem 0}
    .quote{border-left:4px solid var(--accent); padding-left:14px; color:var(--ink-dim); font-style:italic}
    .callout{border:1px solid rgba(110,168,254,.35); background:linear-gradient(180deg, rgba(110,168,254,.10), rgba(110,168,254,.04)); border-radius:12px; padding:14px}
    .table{overflow:auto}
    table{width:100%; border-collapse:collapse; font-size:.96rem}
    th,td{border:1px solid rgba(255,255,255,.12); padding:.6rem; text-align:left; vertical-align:top}
    th{background:rgba(255,255,255,.10)}
    .small{font-size:.92rem; color:var(--ink-dim)}
    .sep{height:1px; background:linear-gradient(90deg, transparent, rgba(255,255,255,.15), transparent); margin:24px 0}
    footer{margin:28px 0 64px; color:var(--muted)}
  </style>
</head>
<body>
<div class="wrap">
  <header class="hero" role="banner">
    <span class="badge"><span class="dot"></span> Updated 2025 · Clinic-precise & Patient-inclusive</span>
    <h1>Autism in Women — What Doctors Still Miss</h1>
    <p class="lead">The female autistic phenotype: masking, burnout, neurobiology, genetics, hormones, and why we still miss it. Part 1 of 2 (Part 2 adds differential diagnosis, interventions, pharmacology & FAQ).</p>
  </header>

  <nav class="toc" aria-label="Table of contents">
    <h2>Contents</h2>
    <a href="#intro">1. Why Women Get Missed</a>
    <a href="#phenotype">2. The Female Phenotype: Masking & Burnout</a>
    <a href="#neuro">3. Neurobiology & Circuits (DMN/Salience/Social/Cerebellum)</a>
    <a href="#sensory">4. Sensory Processing & Predictive Coding</a>
    <a href="#genetics">5. Genetics & Epigenetics (Female Protective Effect)</a>
    <a href="#hormones">6. Neuroendocrinology (Estrogen, Oxytocin, Vasopressin)</a>
    <!-- Part 2 anchors (will be appended below) -->
    <a href="#dx">7. Differential Diagnosis & Comorbidity</a>
    <a href="#assessment">8. Assessment: History, Measures & Pitfalls</a>
    <a href="#interventions">9. Interventions that Help (and What to Avoid)</a>
    <a href="#pharm">10. Adjuvant Pharmacology (Adults)</a>
    <a href="#faq">11. FAQ — Quick Answers</a>
    <a href="#refs">12. References</a>
  </nav>

  <main id="content">
    <!-- =========================
         1) WHY WOMEN GET MISSED
    ========================== -->
    <section id="intro">
      <h2>1. Why Women Get Missed</h2>
      <p>Diagnostic instruments and clinical archetypes were normed predominantly on boys. Many autistic women present with <em>competent performance</em> in brief encounters: eye contact is rehearsed, small talk is scripted, and stimming is suppressed. Clinicians overvalue “what is seen now” and undervalue the <strong>cost ledger</strong> — recovery time, shutdowns after social days, and long-term exhaustion.</p>
      <ul>
        <li><strong>Tool bias:</strong> ADOS-2 sensitivity drops in high-masking profiles; pragmatic language differences can be subtle in structured clinics.</li>
        <li><strong>Context bias:</strong> girls receive prosocial tutoring; imitation can outpace intuition, masking core processing differences.</li>
        <li><strong>Attribution bias:</strong> burnout is misread as depression; blunt truthfulness as personality; sensory refusal as defiance.</li>
      </ul>
      <div class="quote">“She seems fine in session” is not evidence against autism — it’s often evidence of masking.</div>
    </section>

    <!-- =========================
         2) FEMALE PHENOTYPE
    ========================== -->
    <section id="phenotype">
      <h2>2. The Female Phenotype: Masking & Burnout</h2>
      <h3>2.1 Masking (Camouflaging)</h3>
      <p>Masking is a <em>learned compensation</em>: scripted eye contact, memorized conversational slots, mirroring gestures, suppressing self-stimulatory behaviors, and hyper-monitoring others. Short-term gains: fewer conflicts and “passes” as neurotypical. Long-term costs: fatigue, depersonalization, alexithymia, and post-event shutdowns.</p>
      <ul>
        <li><strong>Social scripting:</strong> pre-built phrases, borrowed humor; great in interviews, brittle in improvisation.</li>
        <li><strong>Relational over-functioning:</strong> gifts, apologies, logistical labor to prevent ruptures.</li>
        <li><strong>Interest camouflage:</strong> deep dives into “acceptable” domains (literature, ethics, plants, linguistics) still function as <em>regulatory, rule-based systems</em>.</li>
      </ul>

      <h3>2.2 Burnout</h3>
      <p>Burnout is not “lost motivation.” It is a neurobiological crash after chronic energy-overdraft in misfitting environments. Symptoms: reduced function, shutdowns, poorer sensory tolerance, loss of skills (e.g., cooking variety). Recovery is slower than expected if supports are not adjusted.</p>

      <h3>2.3 Alexithymia & Interoception</h3>
      <p>Many women report difficulty labeling internal states and body signals. Without interoceptive cues, prevention fails and crises seem to “come out of nowhere.” Training a shared lexicon for internal states decreases frequency/intensity of meltdowns.</p>

      <div class="callout"><strong>Clinical translation:</strong> “Apparently fine + privately exhausted” is typical. Ask about recovery windows, not just in-session behavior.</div>
    </section>

    <!-- =========================
         3) NEUROBIOLOGY
    ========================== -->
    <section id="neuro">
      <h2>3. Neurobiology & Circuits (DMN, Salience, Social, Cerebellum)</h2>
      <h3>3.1 Network-level differences</h3>
      <ul>
        <li><strong>Default Mode Network (DMN):</strong> atypical coherence and switching; internal narrative may dominate or be difficult to access, affecting social prediction.</li>
        <li><strong>Salience network (ACC–insula):</strong> altered salience tagging; noisy environments overwhelm; weak tagging in low-context tasks reduces engagement.</li>
        <li><strong>Task-Positive/Executive (DLPFC–parietal):</strong> increased cognitive cost for social inference; masking recruits executive control → metabolic strain.</li>
        <li><strong>Social brain (mPFC, TPJ, STS, amygdala):</strong> timing/connectivity differences affect mentalizing and rapid intention-reading more than “empathy” per se.</li>
        <li><strong>Cerebellum (social cerebellum):</strong> predictive timing and error correction in sequences (speech prosody, turn-taking, gesture timing); subtle dyspraxia adds social friction.</li>
      </ul>

      <h3>3.2 Predictive processing frame</h3>
      <p>Autism can be conceptualized as altered precision weighting of prediction errors. Increased precision on sensory errors → difficulty tolerating uncertainty and change; repetitive behavior minimizes surprise and energy expenditure.</p>

      <h3>3.3 Microcircuitry & glia (clinically relevant)</h3>
      <ul>
        <li><strong>Synaptic balance (E/I):</strong> GABA–glutamate balance differences reported; contributes to sensory hyper-/hypo-reactivity and timing issues.</li>
        <li><strong>Microglia & pruning:</strong> evidence suggests atypical synaptic pruning windows — aligns with uneven skills profile.</li>
      </ul>

      <div class="callout"><strong>Pearl:</strong> Masking “works” because top-down control can override social intuition briefly — at a high energetic cost. The crash is physiology, not attitude.</div>
    </section>

    <!-- =========================
         4) SENSORY & PREDICTIVE CODING
    ========================== -->
    <section id="sensory">
      <h2>4. Sensory Processing & Predictive Coding</h2>
      <p>Women often describe tactile/auditory hypersensitivity in crowded, fluorescent-lit, perfumed spaces. Others report hyposensitivity needing strong input (deep pressure, movement). Both profiles fit a predictive coding model: the brain strives to minimize surprise by seeking controllable input or avoiding chaotic input.</p>
      <ul>
        <li><strong>Hyper-reactivity:</strong> sound (fans, beeps), light (flicker), touch (tags, seams); leads to irritability and shutdowns.</li>
        <li><strong>Hyposensitivity:</strong> seeks deep pressure, tight clothing, rhythmic movement; can be mislabeled “attention seeking.”</li>
        <li><strong>Interoception:</strong> atypical hunger/thirst/fatigue detection → late correction, mood swings.</li>
      </ul>
      <div class="callout"><strong>Practice:</strong> Map triggers; pre-plan exits; offer sensory aids (noise reduction, warm light, weighted items). Function first; cosmetics never.</div>
    </section>

    <!-- =========================
         5) GENETICS & EPIGENETICS
    ========================== -->
    <section id="genetics">
      <h2>5. Genetics & Epigenetics (Female Protective Effect)</h2>
      <p>Pathogenic CNVs/SNVs (e.g., 16p11.2, 22q11.2, SHANK3, CHD8) are more frequently detected in autistic boys. Many autistic women have fewer obvious rare variants but equal impairment, suggesting a <strong>female protective effect</strong> — a higher threshold of mutational/biological burden to express the phenotype. Polygenic risk + epigenetic modulation + environment co-produce outcomes.</p>
      <ul>
        <li><strong>Scaffolding & synapse genes:</strong> SHANK3, NRXN, NLGN families — tiny effect sizes individually, meaningful in aggregate.</li>
        <li><strong>Chromatin & transcription:</strong> CHD8, ADNP, MECP2-related modulation — developmentally timed effects on brain growth and connectivity.</li>
        <li><strong>Oxytocin/vasopressin axis:</strong> OXTR/AVPR polymorphisms variably associated with social processing; effects are modest and context-dependent.</li>
        <li><strong>Epigenetics:</strong> methylation patterns interact with stress, inflammation, hormones — plausibly shaping camouflaging propensity and sensory thresholds.</li>
      </ul>
      <div class="callout"><strong>Counseling:</strong> “No hit on panel” ≠ “not autistic.” Genetic tests inform risks/coordination (e.g., epilepsy, syndromic flags), not identity or validity.</div>
    </section>

    <!-- =========================
         6) NEUROENDOCRINOLOGY
    ========================== -->
    <section id="hormones">
      <h2>6. Neuroendocrinology (Estrogen, Oxytocin, Vasopressin)</h2>
      <h3>6.1 Estrogen</h3>
      <ul>
        <li><strong>Synaptic plasticity:</strong> estradiol enhances glutamatergic plasticity and modulates catecholamines in PFC/hippocampus; cognitive steadiness often peaks mid-cycle.</li>
        <li><strong>Clinical impact:</strong> late luteal/perimenopause → lower tolerance to sensory noise, faster fatigue, more shutdowns. Tracking and adjusting demands/supports across the cycle improves stability.</li>
      </ul>

      <h3>6.2 Oxytocin & Vasopressin</h3>
      <ul>
        <li><strong>Oxytocin:</strong> involved in bonding and stress buffering; trials show mixed results — context, expectations, and baseline traits matter; not a “social cure.”</li>
        <li><strong>Vasopressin:</strong> modulates social vigilance; evidence in humans is preliminary and heterogeneous.</li>
      </ul>

      <h3>6.3 Stress Hormone Interface</h3>
      <ul>
        <li><strong>HPA axis:</strong> unpredictable social/sensory stress elevates cortisol; chronic activation worsens interoceptive confusion and sleep.</li>
        <li><strong>Clinical pearl:</strong> sleep and predictable routines are hormone therapies by other means — they stabilize networks more than many drugs.</li>
      </ul>

      <div class="callout"><strong>Bottom line:</strong> Hormonal state shifts the “noise floor.” Many women aren’t “less capable” premenstrual/perimenopausal; they are <em>more expensively wired</em> that week. Adjust the environment, not self-worth.</div>
    </section>

        <!-- =========================
         7) DIFFERENTIAL DIAGNOSIS & COMORBIDITY
    ========================== -->
    <section id="dx">
      <h2>7. Differential Diagnosis & Comorbidity</h2>
      <p>In women, ASD often looks “fine in clinic” and costly at home. Correct differential requires separating <em>mechanisms</em> (processing/prediction differences) from <em>outcomes</em> (anxiety, depression, avoidance). Co-occurrence is the rule, not the exception.</p>

      <div class="table" style="margin-top:10px">
        <table aria-label="Extended differential">
          <thead>
            <tr><th>Condition</th><th>Overlaps</th><th>How to Distinguish (interview focus)</th></tr>
          </thead>
          <tbody>
            <tr>
              <td><strong>ADHD</strong></td>
              <td>Inattention, procrastination, disorganization, sensation seeking</td>
              <td>ADHD: social intuition intact; novelty-driven. ASD: social inference cost, literal language, need for predictability; many women have both.</td>
            </tr>
            <tr>
              <td><strong>Social Anxiety Disorder</strong></td>
              <td>Social discomfort, eye-contact avoidance</td>
              <td>SAD: fear of negative evaluation; fluency returns when fear drops. ASD: processing cost even when calm; long history of masking and exhaustion.</td>
            </tr>
            <tr>
              <td><strong>PTSD / C-PTSD</strong></td>
              <td>Hypervigilance, shutdowns, avoidance</td>
              <td>PTSD: trajectory linked to events; cue-triggered flashbacks. ASD: developmental onset; sensory/social differences “since always.” Frequently co-present.</td>
            </tr>
            <tr>
              <td><strong>BPD</strong></td>
              <td>Intense affect, relationship ruptures</td>
              <td>BPD: identity instability, abandonment themes, self-harm as dominant regulator. ASD: literal communication, sensory load, restricted interests; strong repair capacity once structure is provided.</td>
            </tr>
            <tr>
              <td><strong>OCD / OCPD</strong></td>
              <td>Routine, rigidity, rituals</td>
              <td>OCD: egodystonic intrusions + compulsions to reduce anxiety. ASD: routines regulate predictability; no classic intrusive thoughts or magical fears.</td>
            </tr>
            <tr>
              <td><strong>Anorexia / ARFID</strong></td>
              <td>Food selectivity, rigid eating</td>
              <td>AN: shape/weight overvaluation central. ARFID/ASD: sensory/interoceptive drivers. Ask “How does food <em>feel</em>?” not only “What do you think about weight?”</td>
            </tr>
            <tr>
              <td><strong>Schizotypal</strong></td>
              <td>Social isolation, unusual style</td>
              <td>Schizotypal: ideas of reference, magical thinking, odd affect. ASD: concrete, literal, systemizing interests; no bizarre content.</td>
            </tr>
            <tr>
              <td><strong>Bipolar II</strong></td>
              <td>Energy variability, many starts</td>
              <td>BP-II: discrete hypomanic episodes (↓sleep, ↑goal-directed activity, grandiosity). ASD: variability tracks tasks, sensory demands, fatigue; no discrete episodes.</td>
            </tr>
          </tbody>
        </table>
      </div>

      <h3>7.1 Common comorbidities</h3>
      <ul>
        <li>ADHD (often camouflaged), social/generalized anxiety, OCD-like presentations, recurrent depression tied to burnout, sleep disorders, chronic pain/hypermobility, migraine, food selectivity/ARFID.</li>
      </ul>
    </section>

    <!-- =========================
         8) ASSESSMENT: HISTORY, MEASURES & PITFALLS
    ========================== -->
    <section id="assessment">
      <h2>8. Assessment: History, Measures & Pitfalls</h2>

      <h3>8.1 History that matters</h3>
      <ul>
        <li>Early social/pragmatic language: literalness, scripted play, “intense best-friend” patterns.</li>
        <li>Masking: onset, how it’s done, cost (recovery time, shutdowns), burnout episodes.</li>
        <li>Special interests: depth, rule-based structure, regulatory function.</li>
        <li>Interoception: hunger/thirst/fatigue signals; difficulty locating feelings (alexithymia).</li>
        <li>Environments: school/work (noise, light, relationships), home (recovery space).</li>
      </ul>

      <h3>8.2 Measures & tools</h3>
      <ul>
        <li><strong>CAT-Q</strong> (Camouflaging Autistic Traits Questionnaire) — quantifies masking.</li>
        <li><strong>RAADS-R</strong>, <strong>AQ</strong> — screening adjuncts; interpret clinically.</li>
        <li><strong>SRS-2</strong> (adult) — dimensional trait severity.</li>
        <li><strong>ADOS-2</strong> — useful but less sensitive in high-masking women; add naturalistic observation and collateral.</li>
        <li><strong>Sensory Profile/SPQ</strong> — sensory map.</li>
        <li><strong>TAS-20</strong> (alexithymia) — guides therapy targets.</li>
      </ul>

      <h3>8.3 Frequent pitfalls</h3>
      <ul>
        <li>Equating eye contact with comfort.</li>
        <li>Over-weighting in-session performance vs lived cost.</li>
        <li>Not asking about recovery time: “How long to reset after a social day?”</li>
        <li>Vague questions; prefer concrete, time-anchored examples.</li>
      </ul>

      <details>
        <summary class="small"><strong>Printable mini-checklist</strong> (adult women — history cues)</summary>
        <ul>
          <li>1) Early arc: first memories of feeling “different” in social contexts.</li>
          <li>2) Masking: when learned, how performed, current cost.</li>
          <li>3) Sensory: top 3 triggers + top 3 calming anchors.</li>
          <li>4) Interests: depth, schedule, regulatory function.</li>
          <li>5) Burnout: count, triggers, symptoms, duration, helpful supports.</li>
          <li>6) Comorbidity: anxiety, ADHD, sleep, pain, eating, migraine.</li>
          <li>7) Environment: adaptations that would lower daily cost.</li>
        </ul>
      </details>
    </section>

    <!-- =========================
         9) INTERVENTIONS THAT HELP (AND WHAT TO AVOID)
    ========================== -->
    <section id="interventions">
      <h2>9. Interventions that Help (and What to Avoid)</h2>

      <h3>9.1 What to avoid</h3>
      <ul>
        <li><strong>Traditional compliance-centric ABA:</strong> suppresses stimming, forces eye contact, relies on reward/punishment to “normalize” appearance. Increases shame, burnout, and trauma risk. <em>Not recommended.</em></li>
      </ul>

      <h3>9.2 What works better (autonomy-respecting, evidence-aligned)</h3>
      <ul>
        <li><strong>NDBI principles</strong> (Naturalistic Developmental Behavioral Interventions): natural contexts, intrinsic interests, co-regulation; target <em>function</em> (communication, autonomy), not camouflage. For adults, translate to naturalistic occupational/social coaching.</li>
        <li><strong>CBT adapted for autism (CBT-a):</strong> concrete language, visuals, stepwise problem solving; modules for uncertainty tolerance, sensory planning. Avoid ambiguous metaphors.</li>
        <li><strong>ACT</strong> (Acceptance & Commitment Therapy): psychological flexibility, values clarification, committed action; helpful for perfectionism and literal rumination.</li>
        <li><strong>DBT-m (modified):</strong> emotion regulation/distress tolerance with sensory anchors (temperature, deep pressure, visual cues); reduces meltdown frequency.</li>
        <li><strong>SST-a</strong> (adapted social skills): role-play, scenarios, “repair scripts”; efficiency over mimicry.</li>
        <li><strong>OT & personalized sensory interventions:</strong> audit light/noise/textures; “calm kit”; refuge spaces. Evidence mixed; pragmatic utility high when individualized.</li>
        <li><strong>Academic & workplace supports:</strong> predictable schedules, sensory breaks, written communication, body-doubling, job crafting.</li>
      </ul>

      <h3>9.3 For partners/family</h3>
      <ul>
        <li>Education about masking and burnout.</li>
        <li>Explicit validation of sensory needs (not “pickiness”).</li>
        <li>Recovery ritual after social events; limit complex conversation during depletion windows.</li>
      </ul>

      <div class="callout"><strong>Golden rule:</strong> target <em>function</em> (communication, autonomy, safety) — not “looking neurotypical.” Camouflage is not therapy.</div>
    </section>

    <!-- =========================
         10) ADJUVANT PHARMACOLOGY (ADULTS)
    ========================== -->
    <section id="pharm">
      <h2>10. Adjuvant Pharmacology (Adults) — Pearls & Cautions</h2>
      <p class="small"><em>Educational. There is no “medication for autism” itself; treat comorbidities and discomfort that blocks function. Individualize, start low, go slow, protect sleep.</em></p>

      <h3>10.1 Anxiety / depression</h3>
      <ul>
        <li><strong>SSRIs</strong> (sertraline, escitalopram): useful for GAD/SAD; watch sensory activation/subjective akathisia; start low.</li>
        <li><strong>SNRIs</strong> (duloxetine, venlafaxine): consider when chronic pain co-occurs; monitor sleep/BP.</li>
        <li><strong>Mirtazapine:</strong> if insomnia/appetite issues dominate; sedating at night.</li>
        <li><strong>Buspirone:</strong> well tolerated as baseline anxiolytic or SSRI adjunct.</li>
      </ul>

      <h3>10.2 Co-occurring ADHD</h3>
      <ul>
        <li><strong>Stimulants</strong> (methylphenidate/amphetamines): can improve initiation/attention; monitor sensory reactivity; early timing; small titrations.</li>
        <li><strong>Atomoxetine</strong>, <strong>Guanfacine ER</strong>, <strong>Viloxazine ER</strong>: alternatives when anxiety/sleep predominate or stimulants are not tolerated.</li>
      </ul>

      <h3>10.3 Irritability / hyper-arousal</h3>
      <ul>
        <li><strong>Risperidone/Aripiprazole:</strong> strongest evidence in pediatrics; in adults use sparingly, low doses, clear goals, metabolic monitoring.</li>
        <li><strong>Propranolol:</strong> useful for somatic hyperarousal (tachycardia/tremor) in performance contexts; avoid in asthma.</li>
        <li><strong>Guanfacine ER</strong> at night: reduces hyperarousal; watch hypotension/daytime sedation.</li>
      </ul>

      <h3>10.4 Sleep</h3>
      <ul>
        <li><strong>Melatonin</strong> 0.5–3 mg, 3–4 h before bedtime (chronobiotic timing).</li>
        <li>Circadian hygiene: morning light, dim evenings, screen filters, predictable wind-down.</li>
      </ul>

      <h3>10.5 <span class="pill">Folate & monoamine pathways (what’s new)</span></h3>
      <ul>
        <li><strong>Folinic acid (leucovorin):</strong> in subgroups (especially pediatric) with folate receptor alpha autoantibodies (FRAA) / suspected cerebral folate deficiency, trials show gains in language/adaptive skills. In adults: limited data; may consider supervised trial when phenotype fits (e.g., migraine, marked fatigue, milk sensitivity) or FRAA+. Monitor GI/insomnia/irritability.</li>
        <li><strong>L-methylfolate:</strong> monoamine cofactor; good evidence as adjunct in treatment-resistant depression. In ASD, potentially helpful when depression/anxiety co-exist or folate polymorphisms are relevant; adult ASD evidence is emerging.</li>
        <li><strong>BH4 (sapropterin):</strong> investigational in select subgroups; adult data limited — specialist settings only.</li>
        <li><strong>N-acetylcysteine (NAC):</strong> some data for irritability/rumination reduction; safe profile; mixed evidence overall.</li>
      </ul>

      <div class="callout"><strong>Key message:</strong> if the core problem is sensory/environmental, dose escalation will not fix cost. Repair sleep and reduce sensory load first; then adjust pharmacology.</div>
    </section>

    <!-- =========================
         11) FAQ — QUICK ANSWERS
    ========================== -->
    <section id="faq">
      <h2>11. FAQ — Quick Answers</h2>

      <details>
        <summary>If she makes eye contact, can she still be autistic?</summary>
        <p>Yes. Many women learn it deliberately. Ask about the <em>cost</em> (fatigue, headache, recovery time).</p>
      </details>

      <details>
        <summary>Why do I “crash” after social events?</summary>
        <p>Masking burns executive control and sensory resources; without buffers, burnout follows. Plan <em>recovery</em>, not just the event.</p>
      </details>

      <details>
        <summary>Is ABA the standard?</summary>
        <p><strong>Traditional ABA</strong> (compliance-focused) is not recommended. <strong>Modern approaches</strong> (NDBI principles, CBT-a, ACT, OT) target function and autonomy and lower shame/cost.</p>
      </details>

      <details>
        <summary>Are there meds for autism?</summary>
        <p>No medication treats “autism itself.” Treat comorbidities (anxiety/ADHD/sleep), reduce sensory load, and build supports. Pharmacology is adjunctive.</p>
      </details>

      <details>
        <summary>Do hormones matter?</summary>
        <p>Yes. Late luteal and perimenopause can worsen sensory tolerance and fatigue. Adjust schedules and expectations in those windows.</p>
      </details>

      <details>
        <summary>What do I tell friends/family?</summary>
        <p>“My brain processes signals differently. Predictability and breaks help me work at my best. With those in place, I’m as capable as anyone.”</p>
      </details>
    </section>

    <!-- =========================
         12) REFERENCES
    ========================== -->
    <section id="refs">
      <h2>12. References (Selected, 2011–2025)</h2>
      <ol>
        <li>Halladay AK, et al. Sex/gender differences in ASD: gaps & priorities. <em>Molecular Autism</em>. 2015.</li>
        <li>Jacquemont S, et al. Higher mutational burden in females — the female protective model. <em>Am J Hum Genet</em>. 2014.</li>
        <li>Gould J, Ashton-Smith J. Missed diagnosis or misdiagnosis? Girls and women on the spectrum. <em>Good Autism Practice</em>. 2011.</li>
        <li>Lai MC, et al. Sex/gender differences and autism. <em>J Am Acad Child Adolesc Psychiatry</em>. 2015.</li>
        <li>Pellicano E, Burr D. Bayesian/predictive coding accounts of autism. Reviews 2014–2020.</li>
        <li>Arnsten AFT. Catecholamine modulation of PFC. <em>Biol Psychiatry</em>. 2009.</li>
        <li>Lombardo MV, et al. Social brain heterogeneity in autism. 2016–2022.</li>
        <li>Hull L, et al. Camouflaging Autistic Traits Questionnaire (CAT-Q). 2019.</li>
        <li>Lever AG, Geurts HM. Aging in ASD (adults): cognition & functioning. 2016–2021 reviews.</li>
        <li>Folinic acid/leucovorin RCTs in FRAA-positive subgroups; systematic reviews (2016–2023).</li>
        <li>Oxytocin trials in ASD — mixed findings, context-dependent (2013–2022).</li>
        <li>Sensory processing & interoception in ASD — scoping/systematic reviews (2018–2024).</li>
      </ol>
      <p class="small">Evidence evolves; this page summarizes robust trends and flags emerging signals (esp. in adults). Educational only — not a substitute for individualized medical advice.</p>
    </section>

    <div class="sep" role="separator" aria-hidden="true"></div>

    <section aria-label="Author">
      <h2>About the Author</h2>
      <p class="small">Written by <strong>Dr. Sarah Ionescu</strong>, psychiatry resident focused on neurodevelopment in women and evidence-aligned, autonomy-respecting care.  
      Learn more or book a consultation: <a href="https://women-and-psychiatry.github.io/women-and-psychiatry-second-opinion.com/index.html" target="_blank" rel="noopener">Women &amp; Psychiatry — Second Opinion</a>.</p>
    </section>
  </main>

  <footer>
    <p class="small">© <span id="y"></span> — Evidence-informed, neurodiversity-affirming resources for women and clinicians.</p>
  </footer>
</div>
<script>document.getElementById('y').textContent = new Date().getFullYear();</script>
</body>
</html>

